Stock compensation plans (Details) - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Aug. 31, 2024 |
Aug. 31, 2023 |
Aug. 31, 2022 |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
| Total stock-based compensation expense | $ 182 | $ 385 | $ 391 |
| Unrecognized compensation cost related to non-vested awards | $ 276 | ||
| Compensation cost not yet recognized period for recognition | 3 years | ||
| 2021 Omnibus Plan | |||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
| Total stock-based compensation expense | $ 73 | 58 | 133 |
| Walgreens health | |||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
| Total stock-based compensation expense | $ 110 | $ 327 | $ 269 |
| X | ||||||||||
- Definition Amount of cost not yet recognized for nonvested award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|